Inspiremd to report fourth quarter and full-year 2023 financial results and provide corporate business update on wednesday, march 6th

-conference call and webcast to be held at 8:30 a.m. est- tel aviv, israel and miami, feb. 28, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) device for the treatment of carotid artery disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on wednesday, march 6th, 2024, before the financial markets open.
NSPR Ratings Summary
NSPR Quant Ranking